Circular Genomics is building a proprietary circular RNA (circRNA) biomarker platform that analyzes highly stable, brain-enriched non-coding RNAs from whole blood to detect neurological disease biology before symptoms appear. Its lead application is an Alzheimer’s disease assay designed to outperform current PET and CSF diagnostics by providing an accessible, pathway-level view of neurodegeneration. The company’s data show robust prediction models, identification of presymptomatic patients, and specificity versus other dementias, positioning the test for use in early screening, patient stratification, and longitudinal monitoring. Beyond Alzheimer’s, Circular Genomics plans to expand its platform into other neurodegenerative and psychiatric conditions such as Parkinson’s disease, major depressive disorder, and bipolar disorder. Near-term priorities include completing large clinical validation studies, enhancing the biomarker panel, forming strategic partnerships with pharma and diagnostic providers, and growing the commercial and scientific teams. The recent $15 million Series A financing provides the capital required to advance these initiatives and prepare the first assay for market launch.

Total raised

$23M

Funding rounds

2

Latest round

Series A

Latest activity

Dec 2025